Lung Cancer Surgery Market

Report Overview

The global lung cancer surgery market was pegged at US$ 5.59 billion in 2021 and is expected to witness a CAGR of 3.5% during the forecast period.

Market Fundamentals 

Lung cancer surgery is used to remove tumour and certain surrounding lung tissues. The type, stage, and location of the lung cancer, along with other medical factors, all influence the nature of procedure. Carcinoid tumours and early-stage non-small cell lung cancer are also included in the procedure. Lung surgery can be divided into four different categories: pneumonectomy, lobectomy, segmentectomy or wedge resection, and sleeve resection.

Market Dynamics

[232423423]

According to the WHO's International Agency for Research on Cancer, outdoor air pollution is an acknowledged carcinogen. Lung cancer incidences are increasing as rise in pollution levels. The market for lung cancer surgery is influenced by this factor. The majority of lung cancer cases are also brought on by long-term smoking. More people are developing lung cancer as a result of the growing smoking population. In addition, the lung cancer surgery market will be driven by both technological developments in the sector and an increase in lung cancer incidences.

Market Ecosystem

The global lung cancer surgery market has been analysed from four perspectives by product, surgery, end user and region.

Lung Cancer Surgery Market by Product

[9808756]

Based on product, the global lung cancer surgery market is segmented into powered instrument, hand instrument, endosurgical equipment and monitoring or visualizing equipment. The hand instruments are sub segmented into clamps, forceps, retractors, staplers, cutters, scissors, elevators, RIB sheers, and trocars, whereas monitoring equipment is sub segmented into camera and trocar. Hand instruments based on the uptake volume of the equipment shall continue to dominate the global market through the forecast period.

Lung Cancer Surgery Market by Surgery 

Based on surgery types, the global lung cancer surgery market is segmented into robotic surgery, thoracotomy, and minimally invasive surgery. The thoracotomy segment is further classified into lobectomy, pneumonectomy, segmentectomy, sleeve resection. The market segment with the largest share was thoracotomy during the forecasted period. However, the minimally invasive surgery segment is anticipated to develop at the greatest CAGR. The reasons driving the growth of this market segment include the rising acceptance of minimally invasive procedures, rising technical breakthroughs, the availability of reimbursement policies, and the rising popularity of robotic surgeries.

Lung Cancer Surgery Market by End User

Based on end user, the global lung cancer surgery market is segmented into hospitals, specialty care centers, ambulatory surgical centers. Hospitals segments dominated the global market during forecast period due to higher patient footfall and better services to patients.

Lung Cancer Surgery Market by Region

The highest incidences of lung cancer have been observed in North America and Asia Pacific. As a result, the market for lung cancer surgery in these two regions is enormous. The rising incidence of lung cancer and the financing choices for surgical treatment of the condition are driving that North America market. The enhanced healthcare infrastructure that facilitates technologically advanced surgeries like robotic surgery is also likely to support market demand. Technical developments in surgical procedures are also projected to support the growth of the global market for lung cancer surgery. Lung cancer has been diagnosed in the majority of patients in the last five years. Tens of thousands of Americans with non-small cell lung cancer receive successful treatment each year.

The prevalence of cancer is significant in Asia Pacific, and awareness initiatives are expanding. The senior population's high prevalence of lung cancer has boosted demand for lung cancer procedures in China. The market for lung cancer surgery in China is expected to expand as a result of the adult population's significant share in lung cancer cases. This is due to the fact that individuals 65 and older account for the majority of lung cancer diagnoses. Lung cancer is rarely found in adults under the age of 45. The WHO predicts that China's elderly population will increase by 28% by 2040.

Competitive Landscape

Some of the key players operating in the global lung cancer surgery market include

• Accuray Inc.,
• Karl storz SE & Co. KG, 
• Teleflex Incorproted
• Richard Wolf GMBH
• Siemens Healthcare 
•  Intutive Surgical Inc.
• Boston Scientific Corporation 
• Angiodynamics
• Olympus Corp. 
• Ethicon Endo surgery Inc.
• Trokamed GmbH
• Phoenix Surgical Holdings Limited
• Scanlan International Inc.
•  KLS Martin Group
• Wexler Surgical Inc.

Strategic Developments

• In May 2021, Endobronchial ultrasound (EBUS) bronchoscope BF-UC190F was launched by Olympus Corporation (Japan). More than 1,600 clinical cases using the Olympus EBUS solution show that EBUS-TBNA (transbronchial needle aspiration) is an efficient biopsy solution, providing higher diagnostic yield with greater sensitivity and specificity in lymph nodes 5 mm.
• In December 2020, Medtronic Private Limited introduced the EEA Circular Stapler with Tri-Staple Technology, the first 3-row Circular Stapler with adjustable height staples in the Indian market.
• In April 2019, Auris Health Inc., a developer of robotic platform technology, was fully acquired by Johnson & Johnson. This acquisition was focused on creating a data-driven, integrated digital ecosystem that combines the industry-leading surgical solutions with cutting-edge technologies to enhance the patient experience.

Frequently Asked Questions About This Report